Table II.
Early results of the working guideline at NICVD
| Disease | Strategy/procedure | COVID-19/pre–COVID-19 months (N) | Outcome (limb salvage), n (%) | Outcome (procedural success), n (%) |
|---|---|---|---|---|
| ALI including vascular injury | Repair/embolectomy/amputation | 204/296 | 171 (83.8)/259 (87.5) | |
| CLTI with tissue loss | Revascularization with or without amputation | 29/98 | 21 (72.4)/82(83.6) | |
| HD access creation | Radiocephalic, brachiocephalic, brachiobasilic transposition, and so forth | 44/66 | 41(93.2)/61 (92.8) | |
| HD access care | Repair of pseudoaneurysm, fistuloplasty | 21/16 | 20 (95.2)/16 (100) | |
| Arterial aneurysm/pseudoaneurysm | Surgical repair | 09/22 | 09 (100)/22 (100) | |
| Total | 307/498 |
COVID-19 months, March through June 2020; pre–COVID-19 months, November 2019 through February 2020.
ALI, acute limb ischemia; CLTI, chronic limb-threatening ischemia; HD, hemodialysis.